Montelukast Was Inefficient in Maintaining Steroid-Induced Remission in Adult Eosinophilic Esophagitis
- 15 June 2011
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 56 (12) , 3551-3558
Abstract
Leukotriene D4 is produced by and functions as a chemotactic factor for eosinophils. Eosinophilic esophagitis (EoE) is characterized by esophageal eosinophilic infiltration, determining structural changes and dismotility symptoms. Montelukast, a selective leukotriene D4 receptor antagonist, has gained increasing consideration as a therapeutic agent for EoE. However, limited available information has shown that montelukast is not effective in reducing eosinophilic infiltration. Our paper aims at evaluating whether montelukast could be consider as a steroid-sparing therapy by assessing its efficacy in maintaining both clinical and histopathological remission achieved after topical corticosteroids in adult EoE patients.Keywords
This publication has 36 references indexed in Scilit:
- Observations on use of montelukast in pediatric eosinophilic esophagitis: insights for the futureDiseases of the Esophagus, 2010
- Esophageal Dysmotility in Children With Eosinophilic EsophagitisAmerican Journal of Gastroenterology, 2009
- The role of mast cells in eosinophilic esophagitisPediatric Allergy and Immunology, 2009
- Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid therapy: a case seriesEndoscopy, 2007
- Food Allergies and Eosinophilic Esophagitis – Two Case StudiesDigestion, 2006
- Eliminating eosinophilic esophagitisClinical Immunology, 2005
- Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseasesJournal of Allergy and Clinical Immunology, 2005
- Pollen and eosinophilic esophagitisJournal of Allergy and Clinical Immunology, 2003
- Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal strictureAnnals of Allergy, Asthma & Immunology, 2003
- MontelukastDrugs, 1998